T
TMRW Life Sciences
Provides an integrated platform for automated, software-guided cryospecimen management
About TMRW Life Sciences
TMRW is a pioneering startup that is revolutionizing the field of assisted reproductive technology. The company has developed the world's first and only automated platform for the safe management and storage of frozen eggs and embryos. This innovative technology is designed to serve fertility clinics and their patients, a market that is growing rapidly due to advances in reproductive technology.
TMRW's business model is centered around providing a much-needed solution to fertility clinics. These clinics are facing increasing demand for egg and embryo storage, and TMRW's platform helps them upgrade, optimize, and safely scale their operations. The platform also offers patients the highest levels of safety, security, and transparency for their precious cells.
The company's platform is FDA-cleared and uses next-generation technology to provide a new standard of care. It includes features such as digital identification and tracking, which provide unprecedented visibility and transparency. The platform's automated technology reduces manual steps and helps eliminate 93% of the potential points of failure. It also includes a 24/7 cloud-based monitoring system for peace of mind.
TMRW generates revenue by selling its platform to fertility clinics. The company's technology has been recognized as a significant advancement in IVF and is trusted by top fertility clinics.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2018
- Headquarters
- New York City, United States
- Employees
- 66
- Open positions
- None listed
- Dealroom signal
- 63.9/100
- Industry
- Health, Security
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Fertility, Biotechnology, Femtech, Arts & Culture, Biotech and Pharma, Reproductive Health, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Apr 2026 | $0 | — | ReproTech | ↗ |
| SERIES DOther financing | Jul 2024 | $28M | $263M | 5AM Ventures · Casdin Capital · Transformation Capital | ↗ |
Growth signals
Latest recorded traffic for TMRW Life Sciences is 5K monthly website visits, up 42.9% over the last three months. TMRW Life Sciences's team declined 9.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
5AM Ventures
Series B and later13 investors entered at this stage
Signature Bank
Transformation Capital
Casdin Capital
Anne Wojcicki
Susan Wojcicki
Peter Thiel
Presight Capital
Life Science Innovations
What If Ventures
GV
G9 Ventures- ASAmy Schumer
Ivf
Other known investors1 additional known investor
ReproTech
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about TMRW Life Sciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TMRW Life Sciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.